Previous 10 | Next 10 |
Summary AngioDynamics posted a pretty clean fiscal second quarter that was a little better than the sell-side expected, and that seemed to drive a meaningful relief rally for the beaten-down shares. Lackluster results from AngioVac/AlphaVac bear watching, given that they're important gr...
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management te...
Inari Medical, Inc. (NARI) Q3 2022 Earnings Conference Call November 02, 2022 4:30 PM ET Company Participants Caroline Corner – Investor Relations Bill Hoffman – President and Chief Executive Officer Drew Hykes – Chief Operating Officer M...
Inari Medical press release ( NASDAQ: NARI ): Q3 GAAP EPS of -$0.19 beats by $0.06 . Revenue of $96.2M (+31.9% Y/Y) beats by $5.37M . Full-Year 2022 Revenue Guidance For the full year 2022, we are increasing our revenue guidance from our previous range of $...
IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter...
Inari Medical ( NASDAQ: NARI ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is -$0.26 and the consensus Revenue Estimate is $90.83M (+24.6% Y/Y). Over the last 3 months, EPS estimates have seen ...
IRVINE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-d...
IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release i...
Inari Medical ( NASDAQ: NARI ) on Monday said a study assessing real-world outcomes for 800 patients in the U.S. who were treated with the company's FlowTriever system for pulmonary embolism (PE) showed a low rate of major adverse events. PE is a condition in which arterie...
IRVINE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the ful...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...